Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma

References

• The Non-Hodgkin's Lymphoma Classification Project (1997) "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project", Blood, 89, 3909— 3918.
   Google Scholar
• Besa, P.C., McLaughlin, P.W., Cox, J.D. and Fuller, L.M. (1995) "Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma", Cancer, 75, 2361–2367.
   Google Scholar
• Gospodarowicz, M.K., Bush, R.S., Brown, T.C. and Chua, T. (1984) "Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience", International Journal of Radiation Oncology, Biology, Physics, 10, 489 —497.
   PubMed Web of Science ®Google Scholar
• Paryani, S.B., Hoppe, R.T., Cox, R.S., Colby, TN., Rosenberg, S.A. and Kaplan, H.S. (1983) "Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II", Cancer, 52, 2300–2307.
   Google Scholar
• Pendlebury, S., elAwadi, M., Ashley, S., Brada, M. and Horwich, A. (1995) "Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma", Radiotherapy and Oncology: Journal of the European Society For Therapeutic Radiology and Oncology, 36, 167— 171.
   PubMed Web of Science ®Google Scholar
• Briggs, J.H., Algan, 0., Miller, T.P. and Oleson, J.R. (2002) "External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma", American Journal of Clinical Oncology: the Official Publication of the American Radium Society, 25, 34–37.
   Google Scholar
• Lambrechts, AC., Hupkes, P.E., Dorssers, L.C. and van't Veer, M.B. (1993) "Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin's lymphoma", Blood, 82, 2510–2516.
   PubMed Web of Science ®Google Scholar
• Monfardini, S., Banfi, A., Bonadonna, G., Rilke, F., Milani, F., Valagussa, P., et al. (1980) "Improved five year survival after combined radiotherapy-chemotherapy for stage I—II non-Hodg-kin's lymphoma", International Journal of Radiation Oncology, Biology, Physics, 6, 125 — 134.
   Google Scholar
• Kelsey, S.M., Newland, AC., Hudson, G.V. and Jelliffe, A.M. (1994) "A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radio-therapy alone in low grade, localised non-Hodgkins lymphoma", Med. Oncol., 11, 19–25.
   Google Scholar
• Carde, P., Burgers, J.M., van Glabbeke, M., Hayat, M., Cosset, J.M., Somers, R., et al. (1984) "Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975— 1980 EORTC controlled lymphoma trial", Radiother. Oncol., 2, 301–312.
   Google Scholar
• Arranz, R., Garcia-Alfonso, P., Sobrino, P., Zamora, P., Carrion, R., Garcia-Larana, J., et al. (1998) "Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicentre trial with double randomization", J. Clin. Oncol., 16, 1538 — 1546.
   Google Scholar
• Teodorovic, I., Pittaluga, S., Kluin-Nelemans, J.C., Meerwaldt, J.H., Hagenbeek, A., van Glabbeke, M., et al. (1995) "Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinico-pathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group", J. Clin. Oncol., 13, 2819 — 2826.
   Google Scholar
• Ozer, H., Wiernik, P.H., Giles, F. and Tendler, C. (1998) "Recombinant interferon-alpha therapy in patients with follicular lymphoma", Cancer, 82, 1821–1830.
   Google Scholar
• O'Connell, M.J., Colgan, J.P., Oken, M.M., Ritts, R.E., Jr., Kay, N.E. and Itri, L.M. (1986) "Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study", J. Clin. Oncol., 4, 128 — 136.
   Web of Science ®Google Scholar
• Decaudin, D., Lepage, E., Brousse, N., Brice, P., Harousseau, J.L., Belhadj, K., et al. (1999) "Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients— a study of the groupe d'Etude des lymphomes de 1"Adulte", J. Clin. Oncol., 17, 2499–2505.
   Web of Science ®Google Scholar
• Foussard, C., Desablens, B., Sensebe, L., Francois, S., Milpied, N., Deconinck, E., et al. (1997) "Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France", Ann. Oncol., 8(Suppl 1), 49— 52.
   Google Scholar
• Aviles, A., Leon, MI., Diaz-Maqueo, J.C., Garcia, E.L., Cleto, S. and Neri, N. (2001) "Rituximab in the treatment of refractory follicular lymphoma — six doses are better than four", J. Hematother. Stem Cell Res., 10, 313— 316.
   Google Scholar
• Solal-Celigny, P. (2001) "Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden", Antic-ancer Drugs, 12\(Suppl 2), S 1 1 — S14.
   Google Scholar
• McLaughlin, P., Hagemeister, F.B. and Grillo-Lopez, A.J. (1999) "Rituximab in indolent lymphoma: the single-agent pivotal trial", Semin. Oncol., 26, 79–87.
   Google Scholar
• Grillo-Lopez, A.J., White, C.A., Yarns, C., Shen, D., Wei, A., McClure, A., et al. (1999) "Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma", Semin. Oncol., 26, 66–73.
   Google Scholar
• Davis, T.A., White, C.A., Grillo-Lopez, A.J., Velasquez, W.S., Link, B., Maloney, D.G., et al. (1999) "Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab", J. Clin. Oncol., 17, 1851–1857.
   PubMed Web of Science ®Google Scholar
• Piro, L.D., White, C.A., Grillo-Lopez, A.J., Janakiraman, N., Saven, A., Beck, T.M., et al. (1999) "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma", Ann. Oncol., 10, 655–661.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, RI., Connors, J.M., et al. (1999) "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group", J. Clin. Oncol., 17, 1244.
   Web of Science ®Google Scholar
• McLaughlin, P., Hagemeister, F.B., Rodriguez, MA., Sarris, A.H., Pate, 0., Younes, A., et al. (2000) "Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma", Semin. Oncol., 27, 37 — 41.
   Google Scholar
• Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Bernstein, Z.P., McCarthy, P., et al. (2002) "Rituximab in combination with CHOP or fludarabine in low-grade lymphoma", Semin. Oncol., 29, 36–40.
   Google Scholar
• Czuczman, M.S. (2002) "Immunochemotherapy in indolent non-Hodgkin's lymphoma", Semin. Oncol., 29, 11 —17.
   Google Scholar
• Jones, SE., Miller, T.P. and Connors, J.M. (1989) "Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy", J. Clin. Oncol., 7, 1186 — 1191.
   Web of Science ®Google Scholar
• Longo, D.L., Glatstein, E., Duffey, P.L., Ihde, D.C., Hubbard, S.M., Fisher, RI., et al. (1989) "Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy", J. Clin. Oncol., 7, 1295–1302.
   Web of Science ®Google Scholar
• Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N. Engl. J. Med., 346, 235–242.
   Google Scholar
• Kluin-Nelemans, H.C. (2002) "Therapy for stage I aggressive non-Hodgkin's lymphoma", Croatian Medical Journal, 43, 546— 549.
   Google Scholar
• Resegotti, L., Vitolo, U., Bertini, M., Brusamolino, E., Comotti, B., Tarella, C., et al. (1991) "MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Co-operative Study Group (IMCSGL)", Leukemia, 5(Suppl 1), 86–89.
   Google Scholar
• McKelvey, E.M., Gottlieb, J.A., Wilson, H.E., Haut, A., Talley, R.W., Stephens, R., et al. (1976) "Hydroxyldaunomycin (Adriamy-cM) combination chemotherapy in malignant lymphoma", Cancer, 38, 1484— 1493.
   Google Scholar
• Fisher, RI., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., et al. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", N. Engl. J. Med., 328, 1002–1006.
   Google Scholar
• Shipp, M.A., Harrington, D.P., Armitage, J.P., Bonadonna, G., Canellos, G.P., Coiffier, B., et al. (1993) "A predictive model for aggressive non-Hodgkin's lymphoma", N. Engl. J. Med., 329, 987 — 994.
   Google Scholar
• Philip, T., Chauvin, F., Armitage, J., Bron, D., Hagenbeek, A., Biron, P., et al. (1991) "Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation", Blood, 77, 1587–1592.
   Google Scholar
• Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., et al. (1995) "Autologous bone marrow transplanta-tion as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", N. Engl. J. Med., 333, 1540–1545.
   Google Scholar
• Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., de Elvira, C.R., et al. (2002) "Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation", Blood, 100, 4310–4316.
   Google Scholar
• Smith, S.M., Grinblatt, D. and van Besien, K. (2002) "Autologous and allogeneic transplantation for aggressive NHL", Cytotherapy, 4, 223–240.
   Google Scholar
• Ratei, R., Matylis, A., Krahl, D., Arnold, R., Stein, H., Dorken, B., et al. (2000) "Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8", Leuk. Lymphoma, 40, 133 — 140.
   PubMed Web of Science ®Google Scholar
• Marcus, K., Buck, B. and Mauch, P.M. (1998) "Principles of radiation therapy for lymphomas", In: The lymphomas, edited by G.P. Canellos, T.A. Lister and J.L. Sklar. pp. 215–234. Philadel-phia: WB Saunders.
   Google Scholar
• Laurent, D., Pradier, 0., Schmidberger, H., Rave-Frank, M., Frankenberg, D. and Hess, CF. (1998) "Radiation rendered more cytotoxic by fludarabine monophosphate in a human oropharynx carcinoma cell-line than in fetal lung fibroblasts", Journal of Cancer Research and Clinical Oncology, 124, 485–492.
   PubMed Web of Science ®Google Scholar
• Gregoire, V., Hunter, N., Brock, WA., Milas, L., Plunkett, W. and Hittelman, W.N. (1994) "Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradia-tion", International Journal of Radiation Oncology, Biology, Physics, 30, 363 — 371.
   Google Scholar
• Gregoire, V., Ang, K.K., Rosier, J.F., Beauduin, M., Garden, AS., Hamoir, M., et al. (2002) "A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma", Radiotherapy and Oncology: Journal of the European Society For Therapeutic Radiology and Oncology, 63, 187— 193.
   PubMed Web of Science ®Google Scholar
• Portlock, CS., Rosenberg, S.A., Glatstein, E. and Kaplan, H.S. (1976) "Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas", Blood, 47, 747–756.
   Google Scholar
• Rosenberg, S.A. (1985) "The low-grade non-Hodgkin's lymphomas: challenges and opportunities", J. Clin. Oncol., 3, 299–310.
   Google Scholar
• Gallagher, CJ., Gregory, W.M., Jones, A.E., Stansfeld, AG., Richards, MA., Dhaliwal, H.S., et al. (1986) "Follicular lympho-ma: prognostic factors for response and survival", J. Clin. Oncol., 4, 1470–1480.
   Web of Science ®Google Scholar
• Canellos, G.P., DeVita, V.T., Young, R.C., Chabner, B.A., Schein, P.S. and Johnson, R.E. (1975) "Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy", British Journal of Cancer, 31\(Suppl 2), 474–480.
   Google Scholar
• Portlock, CS. and Rosenberg, S.A. (1976) "Combination che-motherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas", Cancer, 37, 1275–1282.
   Google Scholar
• Gorin, N.C., David, R., Stachowiak, J., Najman, A. and Duhamel, G. (1977) "Combination of cyclophosphamide, vincristine, and prednisone, followed by maintenance chemotherapy, with and without radiotherapy, in the management of patients with non-Hodgkin's lymphomas", Medical and Pediatric Oncology, 3, 41–51.
   Google Scholar
• Buchi, G., Mazza, U., Camaschella, C., Saglio, G., Cambrin, G.R., Termine, G., et al. (1982) "Chemotherapy of advanced non-Hodgkin lymphomas: a report of 35 cases", Tumori, 68, 307–311.
   Google Scholar
• Cavallin-Stahl, E. and Moller, T.R. (1986) "Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden", Seminars in Oncology, 13, 19–22.
   PubMed Web of Science ®Google Scholar
• Klasa, R.J., Meyer, R.M., Shustik, C., Sawka, CA., Smith, A., Guevin, R., et al. (2002) "Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen", Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20, 4649 —4654.
   PubMed Web of Science ®Google Scholar
• Hagenbeek, A., Eghbali, H., Monfardini, S., Resegotti, E., Hoskin, J., de Wolf-Peeters, C., et al. (2001) "Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized Phase III Intergroup Study in 381 patients", Blood, 98, 315a (Abstract 3501).
   Google Scholar
• Adkins, J.C., Peters, D.H. and Markham, A. (1997) "Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies", Drugs, 53, 1005–1037.
   Google Scholar
• Solal-Celigny, P., Brice, P., Brousse, N., Caspard, H., Bastion, Y., Haioun, C., et al. (1996) "Phase II trial of fludarabine monopho-sphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de 1"Adulte", J. Clin. ()ma, 14, 514–519.
   Google Scholar
• Redman, J.R., Cabanillas, F., Velasquez, W.S., McLaughlin, P., Hagemeister, F.B., Swan, F., et al. (1992) "Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma", J. Clin. °ilea, 10, 790–794.
   PubMed Web of Science ®Google Scholar
• O'Brien, ME., Matutes, E., Cunningham, D., Hill, M., Emmett, E., Ellis, P.A., et al. (1994) "Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience", Leuk. Lym-phoma, 14(Suppl 2), 17–23.
   PubMed Web of Science ®Google Scholar
• Hochster, H.S., Kim, KM., Green, M.D., Mann, R.B., Neiman, R.S., Oken, MM., et al. (1992) "Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study", J. Clin. Oncol., 10, 28–32.
   Web of Science ®Google Scholar
• Shustik, C., Laplante, S. and Meyer, R. (2002) "Cost comparison and cost efficiency analysis between fludarabine (F) and cyclopho-sphamide, vincristine and prednisone (CVP) treatments for low grade non-Hodgkin's lymphoma", Proc. Am. Soc. Clin. Oncol., 21, 282a (Abstract 1172).
   Google Scholar
• Travade, P. (1990) "The experience of the French Cooperative Group in the treatment of CLL", Nouv. Rev. Fr. Hematol., 32, 313 — 317.
   Google Scholar
• Horning, S.J. and Rosenberg, S.A. (1984) "The natural history of initially untreated low-grade non-Hodgkin's lymphomas", N. Engl. J. Med., 311, 1471–1475.
   Google Scholar
• Zinzani P.L. on behalf of an Italian Cooperative Study Group on Lymphoma (2002) "A randomised trial of fludarabine versus CHOP plus rituxumab as first-line treatment in patients with follicular lymphoma", Annals of Oncology, 13\(Suppl 2), 57 (Abstract 185).
   Google Scholar
• Crawley, CR., Foran, J.M., Gupta, R.K., Rohatiner, AZ., Summers, K., Matthews, J., et al. (2000) "A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma", Ann. °ma, 11, 861 — 865.
   Google Scholar
• Cazin, B., Maloum, K., Divine, M., Lepretre, S., Travade, P., Delmer, A., et al. (2002) "Oral fludarabine and cyclophosphamide in previously untreated CLL: Preliminary data on 75 pts", Blood, 100, 206a (Abstract 773).
   Google Scholar
• Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Klippenstein, D., Loud, P., et al. (2001) "Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): Final Report", Blood, 98, 601a (Abstract 2518).
   Google Scholar
• Anderson, K.C., Bates, M.P., Slaughenhoupt, B.L., Pinkus, G.S., Schlossman, S.F. and Nadler, L.M. (1984) "Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation", Blood, 63, 1424–1433.
   PubMed Web of Science ®Google Scholar
• Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., et al. (1998) "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study", Blood, 92, 1927–1932.
   Google Scholar
• Press, 0.W., Appelbaum, F., Ledbetter, JA., Martin, P.J., Zarling, J., Kidd, P., et al. (1987) "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas", Blood, 69, 584— 591.
   Google Scholar
• Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., et al. (2001) "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation", Blood, 97, 101–106.
   Google Scholar
• Igarashi, T., Ohtsu, T., Fujii, H., Sasaki, Y., Morishima, Y., Ogura, M., et al. (2001) "Re-treatment of relapsed indolent B-cell lymphoma with rituximab", International Journal of Hematology, 73, 213–221.
   Google Scholar
• Hainsworth, JD., Litchy, S., Burris, HA., Scullin, D.C., Corso, SM., Yardley, D.A., et al. (2002) "Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma", Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20, 4261 —4267.
   PubMed Web of Science ®Google Scholar
• Czuczman, M.S. (1999) "CHOP plus rituximab chemoimmunother-apy of indolent B-cell lymphoma", Semin. °ma, 26, 88–96.
   Google Scholar
• Press, OM. (1999) "Radioimmunotherapy of non-Hodgkin's lymphoma", Haematologica, 84, 63— 66.
   Google Scholar
• Maloney, D.G., Smith, B. and Rose, A. (2002) "Rituximab: mechanism of action and resistance", Seminars in Oncology, 29, 2–9.
   PubMed Web of Science ®Google Scholar
• Wilson, W.H. (2000) "Chemotherapy sensitization by rituximab: experimental and clinical evidence", Seminars in Oncology, 27, 30–36.
   PubMed Web of Science ®Google Scholar
• Zinzani, P.L., Magagnoli, M., Moretti, L., De Renzo, A., Battista, R., Zaccaria, A., et al. (2000) "Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma", J. Clin. °ilea, 18, 773–779.
   PubMed Web of Science ®Google Scholar
• Pigaditou, A., Rohatiner, AZ., Whelan, JS., Johnson, P.W., Ganjoo, R.K., Rossi, A., et al. (1993) "Fludarabine in low-grade lymphoma", Semin. °ilea, 20, 24–27.
   Google Scholar
• Whelan, JS., Davis, CL., Rule, S., Ranson, M., Smith, 0.P., Mehta, A.B., et al. (1991) "Fludarabine phosphate for the treatment of low grade lymphoid malignancy", Br. J. Cancer., 64, 120–123.
   PubMed Web of Science ®Google Scholar
• Zinzani, P.L., Magagnoli, M., Bendandi, M., Gherlinzoni, F., Orcioni, G.F., Cellini, C., et al. (2000) "Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas", Ann. Oncol., 11, 363–365.
   Google Scholar
• Flinn, I.W., Byrd, J.C., Morrison, C., Jamison, J., Diehl, L.F., Murphy, T., et al. (2000) "Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies", Blood, 96, 71–75.
   Google Scholar
• Lynch, J.W., Hei, DL., Braylan, R.C., Rimzsa, L.M., Staab, E.V., Bewsher, CJ., et al. (2002) "Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-Hodgkin's lymphoma", Am. J. Clin. Oncol., 25, 391–397.
   Web of Science ®Google Scholar
• Seymour, J.F., Grigg, A.P., Szer, J. and Fox, R.M. (2001) "Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders", Ann. Oncol., 12, 1455 — 1460.
   Google Scholar
• McLaughlin, P., Hagemeister, F.B., Romaguera, J.E., Sarris, A.H., Pate, 0., Younes, A., et al. (1996) "Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma", J. Clin. °ilea, 14, 1262— 1268.
   Google Scholar
• Santini, G., Nati, S., Spriano, M., Gallamini, A., Pierluigi, D., Congiu, A.M., et al. (2001) "Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma", Haematologica, 86, 282–286.
   Google Scholar
• Gregory, S.A., Venopusal, P., Adler, S.S., O'Brien, TM., O'Don-nell, K.F. and Yunus, F. (2001) "Safety and efficacy of fludarabine and mitoxantrone with rituximab consolidation in untreated advanced low grade Non-Hodgkin's lymphoma (LG-NHL)", Blood, 98, Abstract 2534.
   Google Scholar
• Foss, F.M., Ihde, D.C., Linnoila, I.R., Fischmann, A.B., Schechter, G.P., Cotelingam, J.D., et al. (1994) "Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/ Sezary syndrome", J. Clin. Oncol., 12, 2051 —2059.
   Web of Science ®Google Scholar